Characterization of von Willebrand factor in factor VIII concentrates

American Journal of Hematology
W A Fricke, M Y Yu

Abstract

Commercial concentrates of factor VIII (FVIII) were analyzed in order to 1) determine the effects of viral inactivation on von Willebrand factor (vWF); 2) evaluate the vWF content of the new, immunopurified concentrates; and 3) assess their potential for correcting the long bleeding time of von Willebrand disease (vWD). Included in our study were products that had been treated to inactivate viruses; older, untreated products; and the new, immunopurified concentrates. We measured von Willebrand factor antigen (vWF:Ag), ristocetin cofactor activity (RCoF), and vWF multimeric and subunit composition. A newly developed radioimmunoassay (RIA) was used to quantitate vWF:Ag. The vWF:Ag content varied from 0.083 micrograms/IU FVIII:C for Hemofil M to 32.2 micrograms/IU FVIII:C for Humate-P, whereas pooled normal human plasma (NHP) contained 6.3 micrograms/IU FVIII:C. The RCoF varied from 0.0007 to 2.09 U/IU FVIII:C, with the immunopurified concentrates having the lowest values and Humate-P the highest. The ratio of RCoF to vWF:Ag ranged from 11 to 96 U/mg, as compared to a ratio of 160 for NHP. All of the concentrates lacked the largest vWF multimers, and all had abnormal triplet patterns. Modest differences between some untreated conc...Continue Reading

References

Dec 1, 1977·British Journal of Haematology·I M Nilsson, U Hedner
Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Feb 28, 1978·Biochemical and Biophysical Research Communications·P J Fraker, J C Speck
Mar 1, 1976·The American Journal of Medicine·D Green, E V Potter
Mar 1, 1988·European Journal of Haematology·E Berntorp, I M Nilsson
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·R B LeveneD C Lynch
Feb 1, 1980·Vox Sanguinis·J P AllainJ P Soulier
Jun 29, 1981·Biochimica Et Biophysica Acta·B A PerretE A Beck

❮ Previous
Next ❯

Citations

Feb 24, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·H J MetznerJ Friedebold
Feb 13, 2001·Transfusion·Y P Agrawal, W Dzik
Mar 1, 1991·British Journal of Haematology·E M SloandW Fricke
Apr 1, 1992·British Journal of Haematology·T FaconJ Goudemand
Jun 21, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·T BurnoufM El-Ekiaby
Sep 17, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·W Schramm
Feb 28, 2006·Biologicals : Journal of the International Association of Biological Standardization·M StadlerT-E Svae
May 1, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·E Berntorp
Mar 1, 1991·American Journal of Hematology·R E WeinsteinF R Rickles
Aug 15, 1998·The American Journal of the Medical Sciences·M D Phillips, A Santhouse
Oct 1, 1990·La Ricerca in Clinica E in Laboratorio·P M MannucciM Cattaneo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.